Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | HINT1 | P49773 | 5/20 | 0.60 |
| ▸ | NT5E | P21589 | 1/20 | 0.58 |
| ▸ | PNP | P00491 | 2/20 | 0.57 |
| ▸ | GSK3A | P49840 | 2/20 | 0.54 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.54 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19831524 | 0.96 | HPGD (0.62) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL1115914 | 0.96 | HPGD (0.62) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL412371 | 0.96 | HPGD (0.62) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL14143259 | 0.96 | HPGD (0.62) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL23425451 | 0.92 | HPGD (0.66) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL21184384 | 0.92 | HPGD (0.74) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL14428958 | 0.92 | HPGD (0.74) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL18763659 | 0.92 | HPGD (0.74) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL18763641 | 0.92 | HPGD (0.74) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL14429010 | 0.92 | HPGD (0.74) | HPGDHINT1NT5EPNPGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185063-A1 | Seven-membered ring nucleosides | IDENIX PHARMACEUTICALS, INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185063-A1 | Seven-membered ring nucleosides | NSUN2, NSUN3, HAVCR2 | HPGD 3914/4885HINT1 385/4885NT5E 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.